GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TYK Medicines Inc (HKSE:02410) » Definitions » Current Deferred Revenue

TYK Medicines (HKSE:02410) Current Deferred Revenue : HK$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TYK Medicines Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

TYK Medicines's current deferred revenue for the quarter that ended in Dec. 2024 was HK$0.00 Mil.

TYK Medicines Current Deferred Revenue Historical Data

The historical data trend for TYK Medicines's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TYK Medicines Current Deferred Revenue Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24
Current Deferred Revenue
- - -

TYK Medicines Quarterly Data
Dec22 Mar23 Jun23 Dec23 Mar24 Jun24 Dec24
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

TYK Medicines Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of TYK Medicines's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


TYK Medicines Business Description

Traded in Other Exchanges
N/A
Address
No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with 12 drug candidates, including Core Product TY-9591, seven products in the clinical stage, and four products in the preclinical stage or early clinical development stage.
Executives
Nan Jing Yi Da Tou Zi Guan Li You Xian Gong Si
Nan Jing Yi Da Zi Ben Guan Li Qi Ye You Xian He Huo
Jiang Su Yi Da Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si
Wu Yusheng 2201 Interest of corporation controlled by you
Zhu Julia Ming 2202 Interest of your spouse
Zheng Zhou Tai Ji Hong Nuo Yi Yao Gu Fen You Xian Gong Si 2101 Beneficial owner
Zhang Xing Li Yuan Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
He Chao 2201 Interest of corporation controlled by you
Bei Jing Hou Ji Jing Qiao Chuang Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Rong Chen Hou Ji Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Zhang Xing Xing Zhang Chan Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

TYK Medicines Headlines

No Headlines